联合临床参数与多参数磁共振成像构建前列腺癌晚期风险模型:个体化风险分层可减少不必要活检
本研究回顾性分析1159例在MRI/经直肠超声融合活检前接受mpMRI的男性,将mpMRI的PI-RADS评分加入ERSPC风险计算器参数构建风险模型,用于预测活检初治及既往活检男性的临床显著性前列腺癌风险。新模型在活检初治男性中AUC为0.83,在既往活检男性中为0.81,决策曲线分析显示可减少不必要活检。
要点
- 将PI-RADS加入ERSPC风险计算器参数构建的风险模型可预测临床显著性前列腺癌。
- 活检初治男性中,新模型AUC为0.83,与ERSPC-RC3联合PI-RADS的0.84相当。
- 既往活检男性中,新模型AUC为0.81,高于PI-RADS的0.78和ERSPC-RC4的0.66。
核心结论
- 结合临床参数与PI-RADS的新型风险模型在预测临床显著性前列腺癌方面显著优于不含PI-RADS的模型,并在活检决策中提供可衡量的获益。
- 对于活检初治患者,新风险模型与ERSPC-RC3联合PI-RADSv1.0的预测性能均优于单独使用临床参数。
研究设计与样本
- 回顾性分析2012至2015年间1159例在MRI/经直肠超声融合活检前接受mpMRI的男性临床参数。
- 采用多变量回归分析确定临床显著性前列腺癌的显著预测因子并构建风险模型。
- 通过受试者工作特征曲线比较风险模型与ERSPC风险计算器、本队列重新拟合的风险计算器、PI-RADS v1.0及ERSPC-RC联合PI-RADSv1.0的预测性能。
- 基于重采样方法评估风险模型的区分度与校准度,并进行净决策与减少曲线分析。
主要发现
- PSA、前列腺体积、直肠指检和PI-RADS是临床显著性前列腺癌的显著预测因子,与年龄一起纳入风险模型。
- 活检初治男性中,风险模型的AUC为0.83,与ERSPC-RC3联合PI-RADSv1.0的0.84相当,高于ERSPC-RC3的0.81、重新拟合RC3的0.80和PI-RADS的0.76。
- 既往活检男性中,新风险模型的区分度AUC为0.81,高于PI-RADS的0.78、ERSPC-RC4的0.66、重新拟合RC4的0.76和ERSPC-RC4联合PI-RADSv1.0的0.78。
- 两个风险模型在决定哪些患者接受活检方面的获益均超过ERSPC风险计算器和PI-RADS,并实现最高的不必要活检减少率。
关键数值与推荐
- 活检初治男性:风险模型AUC 0.83,ERSPC-RC3联合PI-RADSv1.0 AUC 0.84,ERSPC-RC3 AUC 0.81,重新拟合RC3 AUC 0.80,PI-RADS AUC 0.76。
- 既往活检男性:新风险模型AUC 0.81,PI-RADS AUC 0.78,ERSPC-RC4 AUC 0.66,重新拟合RC4 AUC 0.76,ERSPC-RC4联合PI-RADSv1.0 AUC 0.78。
临床怎么用
- 原文未据此给出推荐。
局限性
- 单中心设计。
- 缺乏PI-RADSv2.0。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiparametric magnetic resonance imaging (mpMRI) is gaining widespread acceptance in prostate cancer (PC) diagnosis and improves significant PC (sPC; Gleason score≥3+4) detection. Decision making based on European Randomised Study of Screening for PC (ERSPC) risk-calculator (RC) parameters may overcome prostate-specific antigen (PSA) limitations. OBJECTIVE: We added pre-biopsy mpMRI to ERSPC-RC parameters and developed risk models (RMs) to predict individual sPC risk for biopsy-naïve men and men after previous biopsy. DESIGN, SETTING, AND PARTICIPANTS: We retrospectively analyzed clinical parameters of 1159 men who underwent mpMRI prior to MRI/transrectal ultrasound fusion biopsy between 2012 and 2015. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariate regression analyses were used to determine significant sPC predictors for RM development. The prediction performance was compared with ERSPC-RCs, RCs refitted on our cohort, Prostate Imaging Reporting and Data System (PI-RADS) v1.0, and ERSPC-RC plus PI-RADSv1.0 using receiver-operating characteristics (ROCs). Discrimination and calibration of the RM, as well as net decision and reduction curve analyses were evaluated based on resampling methods. RESULTS AND LIMITATIONS: PSA, prostate volume, digital-rectal examination, and PI-RADS were significant sPC predictors and included in the RMs together with age. The ROC area under the curve of the RM for biopsy-naïve men was comparable with ERSPC-RC3 plus PI-RADSv1.0 (0.83 vs 0.84) but larger compared with ERSPC-RC3 (0.81), refitted RC3 (0.80), and PI-RADS (0.76). For postbiopsy men, the novel RM's discrimination (0.81) was higher, compared with PI-RADS (0.78), ERSPC-RC4 (0.66), refitted RC4 (0.76), and ERSPC-RC4 plus PI-RADSv1.0 (0.78). Both RM benefits exceeded those of ERSPC-RCs and PI-RADS in the decision regarding which patient to receive biopsy and enabled the highest reduction rate of unnecessary biopsies. Limitations include a monocentric design and a lack of PI-RADSv2.0. CONCLUSIONS: The novel RMs, incorporating clinical parameters and PI-RADS, performed significantly better compared with RMs without PI-RADS and provided measurable benefit in making the decision to biopsy men at a suspicion of PC. For biopsy-naïve patients, both our RM and ERSPC-RC3 plus PI-RADSv1.0 exceeded the prediction performance compared with clinical parameters alone. PATIENT SUMMARY: Combined risk models including clinical and imaging parameters predict clinically relevant prostate cancer significantly better than clinical risk calculators and multiparametric magnetic resonance imaging alone. The risk models demonstrate a benefit in making a decision about which patient needs a biopsy and concurrently help avoid unnecessary biopsies.
引用
- Radtke JP, Wiesenfarth M, Kesch C, et al. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. Eur Urol. 2017. PMID: 28400169. doi:10.1016/j.eururo.2017.03.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。